healthy mineMelissa Smith, executive vice president of consulting and professional services, shares six takeaways from the 2023 Medicare Advantage and Part D final rule.Learn how to successfully navigate regulatory updates by click here.
sound health came up with $6 million Seed funding led by M13 with participation from AlleyCorp and Able Partners. The health tech startup’s software platform enables providers to launch and scale their own HIPAA-compliant digital clinics at 80% less cost and time than today.
Capable’s platform guides patient onboarding and enrollment, provides personalized care plans to keep patients on their health goals, and connects patients and providers directly through messaging and video chat.
To read more information, click here.
Image AIA company developing AI-based precision medicine for cancer has raised $21.5 million in a series of financings. It raised $3 million in seed funding led by Blumberg Capital and $18.5 million in Series A funding led by technology-driven cancer drug investors Larry Ellison, Dr. David Agus and AI imaging space pioneer Eyal Gura.
Imagene’s AI diagnostic technology uses digitized biopsy images to perform molecular analysis in real-time as part of its goal to set a new standard for accuracy levels and reduce the time required for results from weeks to minutes.
Imagene’s technology classifies patterns invisible to the human eye, evolving genomics, proteomics and spatial insights to better understand the recurrence of specific cancers and their mechanisms of resistance. The idea is that its technology could better stratify patients in clinical trials and discover new targets for new drugs.
To read more information, click here.
A blog post explores the trend in health tech startups taking risks, in part because public health policy has driven investment in these companies.
“Over the past decade, healthcare executives have partially implemented value-based care and pushed it further through policy. But we are seeing more and more health tech startups willing to take risks. Their care models promise to deliver more frequent care to better meet patients’ needs and help them better manage their condition.”
Jacob Effron’s deep dive on this topic on the Vital Signs blog can be found here. (hat tip Health Tech Nerd)
PolyCore Therapeutics, Inc.a biopharmaceutical company developing treatments for patients with movement and cognitive impairments associated with neurodegenerative diseases, announced that it has received a seed investment from Xontogeny, LLC and Ben Franklin Technology Partners of Southeast Pennsylvania, To advance their lead compound PCT-3012, a novel G protein-biased D3 receptor agonist through IND-supported work reduces dyskinesias in Parkinson’s disease.
picture: Arkindo, Getty Images
